WALL STREET NEWS
PRESSURE BIOSCIENCES INC
Update And Guidance For Strong 2023
Target Price $1.90
Revs Q4 + 93%
Conference Call Tuesday April 18, 2023 4.30pm – 877 545 0523 / Intl 973 528 0016 Access Code 519732
These shares are in BREAKOUT TERRITORY having rapidly advanced to $1.90 over the past 8 weeks before pulling back to current levels . We look for a test once again of the $1.90 level.
The $10+ million of debt exchanged into equity represents over 50% of the total debt currently owed to the Investor by the Company and represents over 30% of the Company’s total outstanding debt held by all investors through February 2023 via (i) convertible promissory notes; (ii) accrued and unpaid interest on convertible promissory notes; and (iii) accrued and unpaid dividends earned from investments in the Company’s Series AA Convertible Preferred Stock financing.
The exchange of debt to equity was consummated at a value of $2.50 per share of Common Stock, which is an approximate 38% premium over the Company’s recent open market valuation.
Pressure BioSciences, Inc. Reports Q4 and FY 2022 Financial Results, Provides Business Update, and Offers Guidance for a Strong 2023
Company Pivots Strongly into Revolutionary UltraShear Platform, Achieving Measurable Progress and Traction, Including Expected Record Revenue in Q1 2023
Investor Call Scheduled for Tuesday, April 18, 2023 at 4:30 p.m. ET
SOUTH EASTON, MA / ACCESSWIRE / April 14, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBI” or the “Company”), a global leader in the development and sale of broadly enabling, high-pressure-based products and services to the life sciences and other industries, reported financial results for the fourth quarter and fiscal year ended December 31, 2022, provided a business update, and offered guidance for a strong 2023, beginning with record revenue in the 2023 first quarter.
Financial Results: Q4 2022 vs. Q4 2021 (rounded to nearest thousand, except EPS)
- Total revenue for Q4 2022 was $607,000 compared to $315,000 for Q4 2021, an increase of 93%.
- Instrument sales for Q4 2022 were $230,000 compared to $116,000 for Q4 2021, an increase of 98%.
- Consumable sales for Q4 2022 were $92,000 compared to $83,000 for Q4 2021, an increase of 11%.
- PBI Agrochem subsidiary sales in Q4 2022 were $71,000 compared to $12,000 for Q4 2021, an increase of 500%.
- Operating loss for Q4 2022 was $1,546,000 compared to $1,221,000 for Q4 2021, an increase of 27%, including an increase in PBI Agrochem inventory reserves of $640,000.
- Basic and diluted net loss per share was $(0.38) for Q4 2022, improved from $(0.57) for Q4 2021.
Financial Results: FY 2022 vs. FY 2021 (rounded to nearest thousand, except EPS)
- Total revenue for 2022 was $1,729,000 compared to $2,002,000 for 2021, a decrease of 14%.
- Instrument sales for 2022 were $724,000 compared to $1,047,000 for 2021, a decrease of 31%.
- Consumable sales for 2022 were $257,000 compared to $274,000 for 2021, a decrease of 6%.
- PBI Agrochem subsidiary sales in 2022 were $165,000 compared to $29,000 for 2021, an increase of 466%.
- Operating loss for 2022 was $4,898,000 compared to $4,185,000 for 2021, an increase of 17%, including an increase in our PBI Agrochem inventory reserves of $640,000.
- Basic and diluted net loss per share was $(1.68) for 2022, improved from $(3.42) for 2021.
Director of Sales and Marketing for PBI, Mr. John B. Hollister, commented: “Impacts of the Covid pandemic supply chain disruptions and economic gyrations undeniably challenged the full year results, while PBI was also deliberately executing on our announced pivot of resources and strategic focus onto our UltraShear Technology (“UST”) platform. Nonetheless, Q4 of 2022 demonstrated a strong rebound in our traditional PCT platform investments, providing welcome underpinning to the revenue growth architecture we have been building for UST in 2023 and beyond, in our march towards significantly increased revenue and profitability.”
2023 Operational and Technical Highlights:
- Major progress in resolving UltraShear manufacturing capacity limitations within current facilities.
- Early data from an on-going, expanded THC marketing study correlates with earlier study results: UST nano-THC oral spray delivering onset in 1-10 (mostly 3-5) minutes, compared to usual onset from typical current edibles at over 45-90 minutes.
- Leading academics in cannabis research expected to publish study results of UST nanoemulsified CBD in April/May 2023, demonstrating definitive superiority in speed of action and total bioavailability over existing marketed products.
- PBI planning for shipments in April against three UST CBD contracts (the $1.5M contract already announced, plus 2 new/additional contracts).
- Beyond early opportunities in CBD/THD, multiple additional UST contract negotiations advancing quickly with announcements pending in cosmeceuticals and immune booster nutraceuticals.
- The Company expects to release Q1 2023 results with record revenue exceeding any quarter in Company’s history and is confidently advancing on announced plans for capacity expansion, balance sheet strengthening, and targeted uplist to NASDAQ or NYSE in 2023.
Mr. Richard T. Schumacher, President and CEO of PBI, added: “As we emerge from a challenging period of economic turbulence and strategic transition, our team has been executing strongly to bring our transformational UltraShear technology to bear on a series of major contract opportunities spanning diverse markets, from nutraceuticals to cosmeceuticals, food and beverages, agrochemicals, and more. We are confident that our pending Q1 2023 announcement of all-time record revenue for any quarter will be quickly superseded by our projected revenue growth through each succeeding quarter in 2023.”
Mr. Jeffrey N. Peterson, PBI’s Chairman, concluded: “The PBI team has demonstrated exceptional tenacity and skill in managing through revolutionary technology platform innovations, early customer cultivation, and successful product and market demonstrations. We are now positioned to secure major UltraShear processing contracts, particularly in the nutraceutical area. Beyond reaching this inflection point in revenue growth, Ric and his team have achieved a major improvement in restructuring the Company’s balance sheet with the significant conversion of debt to equity recently announced. The Company remains focused on completing an up-list to NASDAQ or NYSE in 2023. We are grateful to our dedicated and patient investors and to the PBI team who have delivered us to this pivotal ascension in 2023.”
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB:PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Our primary focus is the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies
Pressure BioSciences and NutraLife Biosciences Renew Partnership for Development and Distribution of Next Generation Nutraceuticals
PBIO’s Patented UltraShear Nanoemulsification Platform is Centerpiece of Renewed Collaboration
SOUTH EASTON, MA / ACCESSWIRE / April 6, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBIO” or the “Company”), a global leader in the development and sale of broadly enabling, high-pressure-based products and services to the life sciences industry, and NutraLife Biosciences (OTC Markets: NLBS) (“NLBS”), a highly-respected manufacturer and distributor of nutraceuticals primarily sold on a direct-to-consumer basis, today announced they have renewed collaborative efforts initiated four years ago. Their fresh partnership is focused on combining PBIO’s Best-in-Class UltraShear Nanoemulsification platform with NLBS’s highly-effective nutraceuticals product formulation, marketing, sales, and distribution capabilities. The companies have just announced their fresh collaboration agreement (“Agreement”), under which PBIO and NLBS will combine their strong, symbiotic capabilities to develop, market, and sell a higher-performing line of next generation nutraceuticals.
Nutraceuticals are typically compositions that offer either or both therapeutic and nutritional effects, including the prevention and treatment of disease (DeFelice 1996). Amongst common nutraceuticals are vitamin supplements, Green Tea Supplements, Omega-3 Fatty Acids, Probiotics and Echinacea. The global nutraceuticals market is expected to reach $991 Billion by 2030 (Research and Markets, Dec 2022).
Mr. Edgar J. Ward, President and CEO of NLBS, explained: “NutraLife is delighted to be once again working with PBIO. As we originally anticipated, their UltraShear technology platform has consistently proven to be superior to other nano technology platforms in multiple critical dimensions, including extended stability, with nearly complete effective water solubility, fast and reliable dose delivery, and vastly increased bioavailability.”
Mr. Ward continued: “Their revolutionary nanoemulsion process will allow us to greatly expand and differentiate our product offerings, giving NLBS a distinct competitive advantage in the nutraceutical marketplace. The UltraShear process transforms products for greatly enhanced efficiency and effectiveness of absorption for targeted nutrients and therapeutic components, delivering the highest quality and reliable results for our consumers. The new “next generation” nutraceuticals that we plan to commercialize, utilizing PBIO’s innovative UltraShear platform, will be marketed and distributed through our expansive existing network of customers, on-line and retail distribution channels.”
Mr. Richard T. Schumacher, President and CEO of PBIO, expanded: “Our UltraShear nanoemulsions platform has left initial collaborators across diverse markets awestruck over the potency and economic efficiencies that we can deliver to their customers and to their bottom line. Our priority has been to select partners who have the existing networks and infrastructure to “hit the ground running” with the uniquely differentiated, superior product opportunities that we offer and enable for them. Edgar and his team at NLBS are precisely what we seek – ready to leverage their extensive existing customer base and market channels to achieve early and rapidly scaling sales traction for innovative and re-engineered products across the nutraceuticals product frontier. In particular, they have been seeking a truly effective nano-CBD tincture solution – and we have that that product already developed and well proven in the hands of independent external experts.”
As previously disclosed, PBIO initiated important bioavailabity studies in both academic and commercial settings over the past year in an effort to support its claim that their revolutionary UltraShear technology platform is a “Best-in-Class” nanoemulsion processing method worldwide. The Company is expecting results from at least one of these on-going studies to be published in a peer-reviewed journal in the coming weeks.
Mr. Schumacher concluded: “Edgar and his team had the technical sophistication to understand and appreciate the power and potential of our UltraShear technology earlier than others, and our teams are now enthusiastically collaborating on several remarkable new product introductions. We expect these breakthrough innovative nutraceutical products to contribute incremental revenues in the millions of dollars for both PBIO and NLBS over the coming years, with substantial revenues for both companies beginning in 2023.”
About NutraLife Biosciences, Inc.
NutraLife Biosciences, Inc. has evolved into a branded and private label developer, distributor, and Food and Drug Administration registered (FDA) manufacturer. NLBS’s products include a range of nutraceutical, wellness, and CBD products as well as a cosmetics line. NutraLife Biosciences’ manufacturing process has earned Good Manufacturing Processes Standard (GMP) certification. Its products adhere to high manufacturing standards throughout every step of the manufacturing and extraction process. NLBS product testing and research & development is conducted by four chemists under the direction of NLBS’s founder and Chief Executive Officer, Edgar Ward.
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB:PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g.,oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies
Pressure BioSciences Reports Fresh Sales Momentum for PBI Agrochem
PBI Agrochem Ships and Bills Initial $130,000 Eco-Friendly Agrochem Order in New Demand Pipeline
SOUTH EASTON, MA / ACCESSWIRE / March 28, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBI” or the “Company”), a global leader in the development and sale of broadly enabling, high-pressure-based products and services to the life sciences and other industries, and its wholly-owned subsidiary PBI Agrochem, Inc. announced it has shipped and billed an initial $130,000 order for its potent, environmentally-responsible nematode control product. The Company also announced that its newly-developed sales channel has provided confidence that an ongoing and growing pipeline of demand is expected to follow for this and other eco-friendly products in the Company’s portfolio.
Global population growth is building inexorable demand for increased food production – while simultaneously, the world is awakening to the challenges and imperatives of environmental sustainability. While usage is soaring for traditional production-boosting synthetic pesticides and fertilizers (despite the persistent environmental threat they create through glacially-slow degradation of toxic components), these older synthetic products are beginning to be eclipsed by new generations of naturally-sourced substances providing potent but environmentally-responsible, eco-friendly agrochemicals.
Mr. John B. Hollister, Director of Sales and Marketing at PBI, explained: “It has required considerable time and effort for us to build fresh relationships and sales channels to serve this burgeoning new market opportunity, which is pivotal to the economic and health trajectories of our planet. As we have begun to establish the PBI Agrochem name in this exciting growth market, we have been consistently told that our thoughtfully organically-sourced and produced eco-friendly agrochem solutions are far superior in potency and value than their older, more expensive, traditional synthetic competitors.”
Mr. Hollister continued: “This incremental $130,000 order from a new business sector has arrived on top of a remarkably strong 1st Quarter 2023 performance to date. Coupled with our recently announced $1.5 Million dollar order for UltraShear toll production of bulk concentrates for CBD products, and further orders now developing in hemp-derived cannabinoids, cosmeceuticals, nutraceuticals, and food/beverage markets, PBI is clearly positioned for commercial take-off during 2023.”
New and old generations of agrochemicals face common challenges in getting a variety of oily (not soluble in water) active ingredients to become effectively absorbed and thus “bioavailable” within their targeted plant species, whose biochemistry is mostly water-based. PBI’s Ultra Shear Technology™ (“UST™” or “UltraShear™”) nanoemulsification platform, which can make oils effectively soluble in water, is a strategic “change agent” technology platform for this market sector and should enable more effective agrochemical dosing while reducing the quantities of expensive active ingredients required. Pesticides, used to control insects that damage crops and severely limit production, are projected to grow in worldwide sales from $84.5 billion in 2019 to $131 billion by 2023. Fertilizers, used to replenish soil with essential nutrients required for better crop growth and production, are expected to achieve global sales of approximately $255 billion by 2027.”
Mr. Richard T. Schumacher, President and CEO of PBI, commented: “This new opportunity offers great strategic impact as an ideal demonstration market for the game-changing impact of our UltraShear nanoemulsions platform on a global industry poised and needy of the benefits we are preparing to deliver. We have already successfully nanoemulsified neem oil and are beginning to study the positive impact that UltraShear processing can have on additional eco-friendly agrochem products.”
Mr. Schumacher concluded: “We continue to work relentlessly on funding our technology and inventory scale-up for growth, while improving our Balance Sheet, and positioning PBIO for a planned up-listing to NASDAQ or NYSE during 2023. This is certainly an exciting moment for all of our stakeholders and for the array of global markets that UltraShear is poised to revolutionize. And as good as things are now, we strongly believe they will only get better as we move further into 2023.”Neither PSN nor its owners, members, officers, directors, partners, consultants, nor anyone involved in the publication of this website, is a registered investment adviser or broker-dealer or associated person with a registered investment adviser or broker-dealer and none of the foregoing make any recommendation that the purchase or sale of securities of any company profiled in the PSN website is suitable or advisable for any person or that an investment or transaction in such securities will be profitable. The information contained in the PSN website is not intended to be, and shall not constitute, an offer to sell nor the solicitation of any offer to buy any security. The information presented in the PSN website is provided for informational purposes only and is not to be treated as advice or a recommendation to make any specific investment. Please consult with an independent investment adviser and qualified investment professional before making an investment decision.d. Writer is paid $925/mo by company